CWM
ABBV icon

Concentrum Wealth Management’s AbbVie ABBV Stock Holding History

Concentrum Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$610K Buy
2,422
+176
+8% +$37.9K 0.15% 65
2026
Q1 		$488K Buy
+2,246
New +$498K 0.14% 65

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Concentrum Wealth Management's ABBV Position: Q2 2026 in Review

Concentrum Wealth Management increased its AbbVie (ABBV) stake by 7.8% in Q2 2026, buying an estimated $37.9K and bringing the position to 2,422 shares worth $610K. The position accounts for 0.15% of the portfolio, ranked #65.

Concentrum Wealth Management first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Concentrum Wealth Management held 2,422 shares of AbbVie worth $610K as of Q2 2026.
  • Concentrum Wealth Management bought 176 AbbVie shares in Q2 2026, an estimated $37.9K.
  • AbbVie made up 0.15% of Concentrum Wealth Management's portfolio in Q2 2026, its #65 holding.
  • Concentrum Wealth Management first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Concentrum Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.